An interim analysis of mid-stage data on Repros' lead therapy Proellex revealed a statistically significant reduction in pain among women suffering from endometriosis. There were no significant differences in response to either the 25 mg or 50 mg dose of the drug and researchers say that most side effects were mild.
- read the release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/repros-therapeutics-inc-announces-proellex-significantly-reduces-pain-u-s-phase-2-cli